LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Significant impact of antibiotic exposure on GI-GVHD, NRM, and GRFS following allogeneic HCT with non-myeloablative Flu-TBI conditioning.

    van Groningen, Lenneke F J / van Dorp, Suzanne / Bremmers, Manita E J / Fazel, Shahira / Roeven, Mieke W H / Blijlevens, Nicole M A / van der Velden, Walter J F M

    Leukemia & lymphoma

    2024  , Page(s) 1–8

    Abstract: Background: Acute gastro-intestinal graft-: Methods: We did a retrospective single-center analysis of patients receiving Flu-TBI-based NMA HCT for a high-grade myeloid malignancy, mostly AML, and MDS, or acute lymphoblastic leukemia (ALL). We ... ...

    Abstract Background: Acute gastro-intestinal graft-
    Methods: We did a retrospective single-center analysis of patients receiving Flu-TBI-based NMA HCT for a high-grade myeloid malignancy, mostly AML, and MDS, or acute lymphoblastic leukemia (ALL). We analyzed the impact of pre-engraftment antibiotic exposure, prophylactic ciprofloxacin, and or treatment with broad-spectrum cephalosporin/carbapenem, on HCT outcomes, with a focus on the incidence of acute GI-GVHD by day 180 and NRM at 1 year.
    Results: A total of 150 patients were evaluable with a median age of 62 years. Antibiotics were used in 90 patients; 60 prophylactic use only and 30 therapeutic use with or without previous prophylaxis. Antibiotic use resulted in a significant higher incidence of GI-GVHD Stage 1-4; 29% (26/90)
    Conclusions: Use of antibiotics was related to the occurrence of GI-GVHD, NRM, and GRFS in patients receiving truly NMA HCT. Therefore, in the absence of mucositis and low incidence of bacteremia, antibiotics can and should be used restrictively in this setting.
    Language English
    Publishing date 2024-03-23
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2024.2331081
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2997: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data.

    Weverling, Flores / Roeven, Mieke / Nijssen, Clara / Broers, Annoek E C / Dovern, Elisabeth / van Rhenen, Anna / Sluis, Geerte van / Hazenberg, Carin L E / Balen, Peter van / Kuipers, Maria T / de Vooght, Karen M K / Morsink, Linde / Kuball, Jürgen / Nur, Erfan / de Witte, Moniek A

    Blood advances

    2024  Volume 8, Issue 7, Page(s) 1683–1686

    MeSH term(s) Humans ; Red-Cell Aplasia, Pure/drug therapy ; Red-Cell Aplasia, Pure/etiology ; Transplantation, Homologous ; Antibodies, Monoclonal/adverse effects
    Chemical Substances daratumumab (4Z63YK6E0E) ; Antibodies, Monoclonal
    Language English
    Publishing date 2024-01-17
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2023011190
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7153: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Immunotherapeutic approaches to treat multiple myeloma.

    Roeven, Mieke W H / Hobo, Willemijn / Schaap, Nicolaas / Dolstra, Harry

    Human vaccines & immunotherapeutics

    2013  Volume 10, Issue 4, Page(s) 896–910

    Abstract: Cellular immunotherapy can be an effective adjuvant treatment for multiple myeloma (MM), as demonstrated by induction of durable remissions after allogeneic stem cell transplantation. However, anti-myeloma immunity is often hampered by suppressive ... ...

    Abstract Cellular immunotherapy can be an effective adjuvant treatment for multiple myeloma (MM), as demonstrated by induction of durable remissions after allogeneic stem cell transplantation. However, anti-myeloma immunity is often hampered by suppressive mechanisms in the tumor micro-environment resulting in relapse or disease progression. To overcome this immunosuppression, new cellular immunotherapies have been developed, based on the important effector cells in anti-myeloma immunity, namely T cells and natural killer cells. These effectors can be modulated to improve their functionality, activated by dendritic cell vaccines, or combined with immune stimulating antibodies or immunomodulatory drugs to enhance their efficacy. In this review, we discuss promising pre-clinical and clinical data in the field of cellular immunotherapy in MM. In addition, we address the potential of combining these strategies with other therapies to maximize clinical effects without increasing toxicity. The reviewed therapies might pave the way to effective personalized treatments for MM patients.
    MeSH term(s) Cell Transplantation/methods ; Combined Modality Therapy/methods ; Humans ; Immunotherapy/methods ; Killer Cells, Natural/immunology ; Multiple Myeloma/therapy ; T-Lymphocytes/immunology
    Language English
    Publishing date 2013-12-11
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2664176-8
    ISSN 2164-554X ; 2164-5515
    ISSN (online) 2164-554X
    ISSN 2164-5515
    DOI 10.4161/hv.27380
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6967: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Decitabine enhances targeting of AML cells by CD34

    Cany, Jeannette / Roeven, Mieke W H / Hoogstad-van Evert, Janneke S / Hobo, Willemijn / Maas, Frans / Franco Fernandez, Rosalia / Blijlevens, Nicole M A / van der Velden, Walter J / Huls, Gerwin / Jansen, Joop H / Schaap, Nicolaas P M / Dolstra, Harry

    Blood

    2017  Volume 131, Issue 2, Page(s) 202–214

    Abstract: Combining natural killer (NK) cell adoptive transfer with hypomethylating agents (HMAs) is an attractive therapeutic approach for patients with acute myeloid leukemia (AML). However, data regarding the impact of HMAs on NK cell functionality are mostly ... ...

    Abstract Combining natural killer (NK) cell adoptive transfer with hypomethylating agents (HMAs) is an attractive therapeutic approach for patients with acute myeloid leukemia (AML). However, data regarding the impact of HMAs on NK cell functionality are mostly derived from in vitro studies with high nonclinical relevant drug concentrations. In the present study, we report a comparative study of azacitidine (AZA) and decitabine (DAC) in combination with allogeneic NK cells generated from CD34
    MeSH term(s) Animals ; Antigens, CD34/analysis ; Antimetabolites, Antineoplastic/therapeutic use ; Azacitidine/therapeutic use ; Cells, Cultured ; Decitabine/therapeutic use ; Gene Deletion ; Humans ; Immunotherapy, Adoptive/methods ; Interleukin Receptor Common gamma Subunit/genetics ; Killer Cells, Natural/transplantation ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/pathology ; Leukemia, Myeloid, Acute/therapy ; Mice, Inbred NOD ; Mice, SCID
    Chemical Substances Antigens, CD34 ; Antimetabolites, Antineoplastic ; Il2rg protein, mouse ; Interleukin Receptor Common gamma Subunit ; Decitabine (776B62CQ27) ; Azacitidine (M801H13NRU)
    Language English
    Publishing date 2017-11-14
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2017-06-790204
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Efficient nontoxic delivery of PD-L1 and PD-L2 siRNA into dendritic cell vaccines using the cationic lipid SAINT-18.

    Roeven, Mieke W H / Hobo, Willemijn / van der Voort, Robbert / Fredrix, Hanny / Norde, Wieger J / Teijgeler, Kasper / Ruiters, Marcel H J / Schaap, Nicolaas / Dolstra, Harry

    Journal of immunotherapy (Hagerstown, Md. : 1997)

    2015  Volume 38, Issue 4, Page(s) 145–154

    Abstract: Dendritic cell (DC)-based vaccination is an appealing strategy to boost graft-versus-tumor immunity after allogeneic stem cell transplantation (allo-SCT), and thereby prevent or counteract tumor recurrence. By exploiting minor histocompatibility antigens ...

    Abstract Dendritic cell (DC)-based vaccination is an appealing strategy to boost graft-versus-tumor immunity after allogeneic stem cell transplantation (allo-SCT), and thereby prevent or counteract tumor recurrence. By exploiting minor histocompatibility antigens (MiHA) presented on hematopoietic cells, donor CD8 T-cell immunity can be selectively targeted to patient's hematological tumor cells without the risk of inducing graft-versus-host disease. Previously, we demonstrated that silencing RNA (siRNA) of programmed death-ligand 1 (PD-L1) and PD-L2 on DCs markedly augments the expansion and function of MiHA-specific CD8 T cells. However, previously applied methods based on electroporation or lipid nanoparticles were either incompatible with target antigen mRNA delivery or required complex manufacturing compliant to Good Manufacturing Practice. Here, we investigated whether transfection using lipoplexes composed of PD-L1 and PD-L2 siRNAs plus SAINT-18:DOPE (ie, SAINT-RED) is an effective and feasible clinical-grade method in DC vaccine manufacturing. We observed that a single siRNA/SAINT-RED transfection resulted in efficient and long-term knockdown of the PD-1 ligands without affecting DC maturation or viability. Furthermore, we demonstrated that SAINT-RED can be heat sterilized without loss of function, facilitating its use in aseptic DC vaccine production. Finally, we showed that the established transfection method can be combined with target antigen mRNA or peptide loading to efficiently stimulate MiHA-specific T-cell expansion and cytokine production. Together, these findings indicate that the developed PD-L siRNA/SAINT-RED transfection protocol in combination with MiHA mRNA or peptide loading can be applied in the generation of clinical-grade DC vaccines to boost antitumor immunity after allo-SCT.
    MeSH term(s) B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/genetics ; CD8-Positive T-Lymphocytes/immunology ; Cancer Vaccines/immunology ; Cell Proliferation ; Clone Cells ; Cytokines/metabolism ; Dendritic Cells/immunology ; Graft vs Tumor Effect/genetics ; Hematopoietic Stem Cell Transplantation ; Humans ; Minor Histocompatibility Antigens/immunology ; Neoplasms/therapy ; Programmed Cell Death 1 Ligand 2 Protein/antagonists & inhibitors ; Programmed Cell Death 1 Ligand 2 Protein/genetics ; Pyridinium Compounds/chemistry ; RNA, Small Interfering/genetics ; Transfection/methods ; Transplantation, Homologous
    Chemical Substances 1-methyl-4-(9-dioleyl)methylpyridinium ; B7-H1 Antigen ; Cancer Vaccines ; Cytokines ; Minor Histocompatibility Antigens ; PDCD1LG2 protein, human ; Programmed Cell Death 1 Ligand 2 Protein ; Pyridinium Compounds ; RNA, Small Interfering
    Language English
    Publishing date 2015-05
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1064067-8
    ISSN 1537-4513 ; 1053-8550 ; 1524-9557
    ISSN (online) 1537-4513
    ISSN 1053-8550 ; 1524-9557
    DOI 10.1097/CJI.0000000000000071
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1778: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: The Aryl Hydrocarbon Receptor Antagonist StemRegenin1 Improves In Vitro Generation of Highly Functional Natural Killer Cells from CD34(+) Hematopoietic Stem and Progenitor Cells.

    Roeven, Mieke W H / Thordardottir, Soley / Kohela, Arwa / Maas, Frans / Preijers, Frank / Jansen, Joop H / Blijlevens, Nicole M / Cany, Jeannette / Schaap, Nicolaas / Dolstra, Harry

    Stem cells and development

    2015  Volume 24, Issue 24, Page(s) 2886–2898

    Abstract: Early natural killer (NK)-cell repopulation after allogeneic stem cell transplantation (allo-SCT) has been associated with reduced relapse rates without an increased risk of graft-versus-host disease, indicating that donor NK cells have specific ... ...

    Abstract Early natural killer (NK)-cell repopulation after allogeneic stem cell transplantation (allo-SCT) has been associated with reduced relapse rates without an increased risk of graft-versus-host disease, indicating that donor NK cells have specific antileukemic activity. Therefore, adoptive transfer of donor NK cells is an attractive strategy to reduce relapse rates after allo-SCT. Since NK cells of donor origin will not be rejected, multiple NK-cell infusions could be administered in this setting. However, isolation of high numbers of functional NK cells from transplant donors is challenging. Hence, we developed a cytokine-based ex vivo culture protocol to generate high numbers of functional NK cells from granulocyte colony-stimulating factor (G-CSF)-mobilized CD34(+) hematopoietic stem and progenitor cells (HSPCs). In this study, we demonstrate that addition of aryl hydrocarbon receptor antagonist StemRegenin1 (SR1) to our culture protocol potently enhances expansion of CD34(+) HSPCs and induces expression of NK-cell-associated transcription factors promoting NK-cell differentiation. As a result, high numbers of NK cells with an active phenotype can be generated using this culture protocol. These SR1-generated NK cells exert efficient cytolytic activity and interferon-γ production toward acute myeloid leukemia and multiple myeloma cells. Importantly, we observed that NK-cell proliferation and function are not inhibited by cyclosporin A, an immunosuppressive drug often used after allo-SCT. These findings demonstrate that SR1 can be exploited to generate high numbers of functional NK cells from G-CSF-mobilized CD34(+) HSPCs, providing great promise for effective NK-cell-based immunotherapy after allo-SCT.
    MeSH term(s) Antigens, CD34/genetics ; Antigens, CD34/metabolism ; Cell Differentiation ; Cells, Cultured ; Cyclosporine/pharmacology ; Hematopoietic Stem Cells/cytology ; Hematopoietic Stem Cells/drug effects ; Hematopoietic Stem Cells/metabolism ; Humans ; Interferon-gamma/genetics ; Interferon-gamma/metabolism ; Killer Cells, Natural/cytology ; Killer Cells, Natural/drug effects ; Killer Cells, Natural/metabolism ; Purines/pharmacology ; Receptors, Aryl Hydrocarbon/antagonists & inhibitors
    Chemical Substances Antigens, CD34 ; Purines ; Receptors, Aryl Hydrocarbon ; StemRegenin 1 ; Interferon-gamma (82115-62-6) ; Cyclosporine (83HN0GTJ6D)
    Language English
    Publishing date 2015-12-15
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2142214-X
    ISSN 1557-8534 ; 1547-3287
    ISSN (online) 1557-8534
    ISSN 1547-3287
    DOI 10.1089/scd.2014.0597
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3616: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Successful Transfer of Umbilical Cord Blood CD34

    Dolstra, Harry / Roeven, Mieke W H / Spanholtz, Jan / Hangalapura, Basav N / Tordoir, Marleen / Maas, Frans / Leenders, Marij / Bohme, Fenna / Kok, Nina / Trilsbeek, Carel / Paardekooper, Jos / van der Waart, Anniek B / Westerweel, Peter E / Snijders, Tjeerd J F / Cornelissen, Jan / Bos, Gerard / Pruijt, Hans F M / de Graaf, Aniek O / van der Reijden, Bert A /
    Jansen, Joop H / van der Meer, Arnold / Huls, Gerwin / Cany, Jeannette / Preijers, Frank / Blijlevens, Nicole M A / Schaap, Nicolaas M

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2017  Volume 23, Issue 15, Page(s) 4107–4118

    Abstract: Purpose: ...

    Abstract Purpose:
    Language English
    Publishing date 2017-08-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-16-2981
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4223: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top